Your browser doesn't support javascript.
loading
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.
Liang, Sheng-Kai; Hsieh, Min-Shu; Lee, Meng-Rui; Keng, Li-Ta; Ko, Jen-Chung; Shih, Jin-Yuan.
Afiliación
  • Liang SK; Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
  • Hsieh MS; Department of Pathology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Lee MR; Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
  • Keng LT; Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
  • Ko JC; Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
  • Shih JY; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Oncotarget ; 8(52): 90430-90443, 2017 Oct 27.
Article en En | MEDLINE | ID: mdl-29163842
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Taiwán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Taiwán